1. VP Biden Addresses Researchers @ ASCO16

    Speaking from the heart, Vice President Joseph Biden addressed thousands of cancer researchers today in a packed hall at the American Society of Clinical Oncology (#ASCO16) annual meeting in Chicago, to tout his Cancer Moonshot initiative. The theme of this year’s #ASCO16 meeting, “Collective Wisdom – The Future of Patient-Centered Care and Research,” is perfectly aligned with the goals of the Moonshot, Biden told the rapt audience.

    Read More
  2. Precision Medicine and Immunotherapy @ ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago. CPX-351: A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly pati...

    Read More
  3. Putting Patients at the Center of Care at #ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients. Putting patients at the center of cancer care and research is this year’s theme at ASCO, something we at The Leukemia & Lymphoma Society (LLS) try to do every day. Sprin...

    Read More
  4. Staying One Step Ahead of Myeloma – and Counting on New Research

    Myeloma is a beast. It is a complicated cancer with no cure and, with so many different types, no two patients are the same. Drugs can put it into remission, but it almost always comes back. And when it does, it’s a little more aggressive and needs to be attacked in a different way. This is knowledge I’ve been living with for four years now and I’m doing everything I can to stay one step ahead of my disease. Believing there was a cure down the line, I opted for a clinical tri...

    Read More
  5. The Bright Light (Actually Two!) at the End of the Tunnel

    I was 28, married for two years, and my husband and I had just celebrated our one-year anniversary at my business, Gigi’s Cupcakes. We were happy and healthy and ready to start thinking about having a family. Life was perfect! On March 30, 2012, that all changed. I had gone to see my physician for bruising on my legs. After undergoing a couple of lab tests, my doctor informed me that in all his years of medicine, he had never seen a white blood cell count that high. He couldn’t fathom ...

    Read More
  6. Rest, Relax & Renew

    Anxiety is a real and true problem for about 40 million American adults—and lots of them are not even part of the nation’s cancer cohort. For many people with cancer, trying to eject the big C from the front of their minds is tough to do. After weeks or months of treatments to get to remission, or receiving a chronic cancer diagnosis with a wait-and-see approach until treatment is needed (what one of my friends terms “medical limbo”), it is certainly a challenge to get past the anx...

    Read More
  7. Finding New Approaches to Immunotherapy

    Helen Heslop, M.D., leads a team of scientists being funded through LLS’s Specialized Center of Research Program (SCOR). The project brings together researchers from different institutions to test a half dozen novel approaches to cancer immunotherapy – all of which harness the patient's own immune system to fight the cancer. Heslop, a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy, pioneered...

    Read More
  8. LLS e-Newsletters

    Let us do the work for you. Receive a monthly email with the latest disease-specific news, research studies, clinical trials and support resources for people living with blood cancer. Sign up here to subscribe to Leukemia Links, Lymphoma Links, Myeloma Links, and eNewsline.

    Read More
  9. Significant Advance for Hodgkin Lymphoma Patients

    The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...

    Read More
  10. Diagnosed with a Blood Cancer? Important Questions You Might Not Think to Ask

    What is my actual diagnosis? Find out your exact diagnosis. Ask your doctor to write down the exact name of your sub-type and take the paper with you. For example, knowing you have “a B-cell lymphoma” isn’t good enough. Follicular and diffuse large B-cell are both B-cell lymphomas but with very different prognoses and treatment plans. Leukemia also has different sub-types. Knowing your specific sub-type helps you understand what disease you are dealing with, how aggressive it is, and wh...

    Read More